MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Total Assets 2011-2026 | OPK
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.2 B | 2.01 B | 2.17 B | 2.4 B | 2.47 B | 2.31 B | 2.45 B | 2.58 B | 2.77 B | 2.8 B | 1.27 B | 1.39 B | 290 M | 229 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.8 B | 229 M | 1.95 B |
Quarterly Total Assets OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.97 B | 2.13 B | 2.26 B | 1.98 B | 1.97 B | 2.06 B | 2.16 B | 2.17 B | 2.17 B | 2.22 B | - | 2.31 B | 2.4 B | 2.42 B | 2.42 B | 2.52 B | 2.47 B | 2.47 B | 2.47 B | 2.47 B | 2.31 B | 2.31 B | 2.31 B | 2.31 B | 2.45 B | 2.45 B | 2.45 B | 2.45 B | 2.59 B | 2.59 B | 2.59 B | 2.59 B | 2.77 B | 2.77 B | 2.77 B | 2.77 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 1.27 B | 1.27 B | 1.27 B | 1.27 B | 1.39 B | 1.39 B | 1.39 B | 1.39 B | 290 M | 290 M | 290 M | 290 M | 229 M | 229 M | 229 M | 229 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.8 B | 229 M | 1.95 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
5.94 M | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
531 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
6.34 B | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | $ 104.91 | - | $ 19.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
73.6 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Interpace Biosciences
IDXG
|
14.8 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
3.35 B | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Agilent Technologies
A
|
10.7 B | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
110 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
2.01 B | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
413 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Celcuity
CELC
|
245 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
4.45 M | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
1.39 B | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.39 | 4.51 % | $ 417 M | USA |
 |
RadNet
RDNT
|
3.76 B | $ 61.74 | 0.41 % | $ 4.64 B | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |